Albany Molecular Research (AMRI) Tops Q3 EPS by 4c
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Albany Molecular Research (NASDAQ: AMRI) reported Q3 EPS of $0.17, $0.04 better than the analyst estimate of $0.13. Revenue for the quarter came in at $151.7 million versus the consensus estimate of $160.75 million.
For earnings history and earnings-related data on Albany Molecular Research (AMRI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vera Bradley (VRA) Tops Q3 EPS by 1c; Offers Light Q4 Outlook; Enters New Licensing Agreements
- John Wiley & Sons (JW-A) Tops Q2 EPS by 9c
- Dave & Buster's Entertainment (PLAY) Tops Q3 EPS by 11c, Raises FY Revenue Guidance
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!